Analyst Price Target is $13.00
▲ +73.56% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Sensei Biotherapeutics in the last 3 months. The average price target is $13.00, with a high forecast of $14.00 and a low forecast of $12.00. The average price target represents a 73.56% upside from the last price of $7.49.
Current Consensus is
The current consensus among 5 investment analysts is to buy stock in Sensei Biotherapeutics.
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.